In gliomas, NG2/CSPG4 is emerging as a potential tumor-associated antigen (TAA) [65,66,67,68,69,70] for antibody-based immunotherapy, using chimeric antigen receptor-based T cell (CAR-Ts) therapy in patients with GB [47]. The gene discussed is CSPG4; the disease is central nervous system cancer.